ENDRA Life Sciences Inc. (NASDAQ: NDRA) reported its financial results for the third quarter ended September 30, 2026, and provided a business update regarding a proposed merger with Noble Africa LLC. The company announced that cash used in operations during the third quarter of 2026 was $1.8 million, compared to $1.2 million in the same period of 2025. This increase was primarily attributed to higher professional fees related to the proposed merger, digital asset management, and performance fees.

Operating expenses for the third quarter of 2026 totaled $1.7 million, compared to $1.4 million in the prior year. Research and development expenses decreased to approximately $176,000 from $432,000 in the comparable prior-year period. Conversely, general and administrative expenses rose to $1.5 million from $893,000 in the prior year, largely due to costs associated with merger-related activities. The net loss for the quarter was $1.5 million, an improvement from the $1.6 million net loss reported in the third quarter of 2025. This improvement was driven by approximately $187,000 of net other income in 2026, compared to approximately $225,000 of net other expense in the prior year.

As of September 30, 2026, ENDRA reported $1.5 million in unrestricted cash, $3.4 million in restricted cash, and $1.3 million in digital assets. The restricted cash is associated with a financing completed in May 2026 and related contractual obligations.

In a separate business update, ENDRA stated it is working to advance its proposed merger with Noble Africa, a subsidiary of ASP Isotopes Inc. (NASDAQ: ASPI). Under the terms of the merger agreement announced on June 25, 2026, Noble Africa will become a wholly owned subsidiary of ENDRA, and ENDRA will be renamed 4K Resources Inc. The transaction includes a concurrent private placement expected to raise approximately $50 million in gross proceeds. The company noted that the transaction remains subject to customary closing conditions, including stockholder approvals, the effectiveness of a registration statement on Form S-4, and compliance with Nasdaq listing requirements.